Joseph G. Ibrahim
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
With the robust uptick in the applications of Bayesian external data borrowing, eliciting a prior distribution with the proper amount of information becomes increasingly critical. The prior effective sample size (ESS) is an intuitive and efficient measure for this purpose. The majority of ESS definitions have been proposed in the context of borrowing control information. Meanwhile, Bayesian borrowing is frequently conducted on the treatment effect scale to extrapolate evidence in pediatric or global trials. While many Bayesian models can be naturally extended to leveraging external information on the treatment effect scale, very little attention has been directed to computing the prior ESS in this setting. In this research, we bridge this methodological gap by extending the popular expected local information ratio (ELIR) ESS definition. We lay out the general framework, and derive the ESS for various types of endpoints and treatment effect measures. The desirable predictive consistency property of ELIR ESS is examined and found to only be preserved for the difference between two normal endpoints. The methods are implemented in R programs available on GitHub: https://github.com/squallteo/TrtEffESS .
Year:
2025
Factor analysis provides an intuitive approach for dimension reduction when working with big data, allowing researchers to represent an extensive number of correlated variables via a subset of underlying latent factors. Traditional methods of factor analysis, such as Structural Equation Modeling (SEM) and factor regression, lack properties desirable for analyzing big data, such as the ability to handle high‐dimensionality or the ability to enforce sparsity on the estimates of the factor loading matrices. These methods also assume that the number of latent constructs is known beforehand, a problem unique to factor analysis that often goes unaddressed or overlooked, with ad hoc methods being the most common ways to deal with such a fundamental question. Although recent developments in the literature have attempted to remedy these issues, particularly with regard to expanding SEM to high‐dimensional and sparse applications, there is a noticeable lack of such methods that do so using likelihood theory. To rectify this shortcoming, we propose a new SEM‐based method for estimation that utilizes maximum likelihood theory while simultaneously addressing some of the most common problems associated with big data. We substantiate our method through simulation studies, indicating that the proposed method can correctly identify the latent factors underlying the independent and dependent sets of variables, while also accurately estimating the entries of and enforcing sparsity upon the factor loading matrix estimates. We apply this method to the COVIDiSTRESS Global Survey dataset, a global survey collected to further our understanding of how the COVID‐19 pandemic affected the human experience. Doing so demonstrates the performance of the model while simultaneously identifying the latent constructs intrinsic to the data.
Year:
2025
Identifying and characterizing relationships between treatments, exposures, or other covariates and time‐to‐event outcomes has great significance in a wide range of biomedical settings. In research areas such as multi‐center clinical trials, recurrent events, and genetic studies, proportional hazard mixed effects models (PHMMs) are used to account for correlations observed in clusters within the data. In high dimensions, proper specification of the fixed and random effects within PHMMs is difficult and computationally complex. In this paper, we approximate the proportional hazards mixed effects model with a piecewise constant hazard mixed effects survival model. We estimate the model parameters using a modified Monte Carlo expectation conditional minimization (MCECM) algorithm, allowing us to perform variable selection on both the fixed and random effects simultaneously. We also incorporate a factor model decomposition of the random effects in order to more easily scale the variable selection method to larger dimensions. We demonstrate the utility of our method using simulations, and we apply our method to a multi‐study pancreatic ductal adenocarcinoma gene expression dataset to select features important for survival.
Year:
2025
In oncology clinical trials, tumor burden (TB) stands as a crucial longitudinal biomarker, reflecting the toll a tumor takes on a patient's prognosis. With certain treatments, the disease's natural progression shows the tumor burden initially receding before rising once more. Biologically, the point of change may be different between individuals and must have occurred between the baseline measurement and progression time of the patient, implying a random effects model obeying a bound constraint. However, in practice, patients may drop out of the study due to progression or death, presenting a non‐ignorable missing data problem. In this paper, we introduce a novel joint model that combines time‐to‐event data and longitudinal data, where the latter is parameterized by a random change point augmented by random pre‐slope and post‐slope dynamics. Importantly, the model is equipped to incorporate covariates across the longitudinal and survival models, adding significant flexibility. Adopting a Bayesian approach, we propose an efficient Hamiltonian Monte Carlo (HMC) algorithm for parameter inference. We demonstrate the superiority of our approach compared to a longitudinal‐only model via simulations and apply our method to a data set in oncology. The code for implementation is publicly available on https://github.com/quyixiang/chgptModel .
Year:
2025
Postmarket drug safety database like vaccine adverse event reporting system (VAERS) collect thousands of spontaneous reports annually, with each report recording occurrences of any adverse events (AEs) and use of vaccines. We hope to identify signal vaccine‐AE pairs, for which certain vaccines are statistically associated with certain adverse events (AE), using such data. Thus, the outcomes of interest are multiple AEs, which are binary outcomes and could be correlated because they might share certain latent factors; and the primary covariates are vaccines. Appropriately accounting for the complex correlation among AEs could improve the sensitivity and specificity of identifying signal vaccine‐AE pairs. We propose a two‐step approach in which we first estimate the shared latent factors among AEs using a working multivariate logistic regression model, and then use univariate logistic regression model to examine the vaccine‐AE associations after controlling for the latent factors. Our simulation studies show that this approach outperforms current approaches in terms of sensitivity and specificity. We apply our approach in analyzing VAERS data and report our findings.
Year:
2024
Tumors are comprised of a mixture of distinct cell populations that differ in terms of genetic makeup and function. Such heterogeneity plays a role in the development of drug resistance and the ineffectiveness of targeted cancer therapies. Insight into this complexity can be obtained through the construction of a phylogenetic tree, which illustrates the evolutionary lineage of tumor cells as they acquire mutations over time. We propose Canopy2, a Bayesian framework that uses single nucleotide variants derived from bulk DNA and single-cell RNA sequencing to infer tumor phylogeny and conduct mutational profiling of tumor subpopulations. Canopy2 uses Markov chain Monte Carlo methods to sample from a joint probability distribution involving a mixture of binomial and beta-binomial distributions, specifically chosen to account for the sparsity and stochasticity of the single-cell data. Canopy2 demystifies the sources of zeros in the single-cell data and separates zeros categorized as non-cancerous (cells without mutations), stochastic (mutations not expressed due to bursting), and technical (expressed mutations not picked up by sequencing). Simulations demonstrate that Canopy2 consistently outperforms competing methods and reconstructs the clonal tree with high fidelity, even in situations involving low sequencing depth, poor single-cell yield, and highly-advanced and polyclonal tumors. We further assess the performance of Canopy2 through application to breast cancer and glioblastoma data, benchmarking against existing methods. Canopy2 is an open-source R package available at https://github.com/annweideman/canopy2 .
Year:
2024
Collaborators (2)
Yuchao Jiang
Associate Professor
Texas A&M University
Ethan Alt
Assistant Professor
University of North Carolina at Chapel Hill
Make your next move.
Prepare your application
Review drafts before you send them.